Elliott, Robin

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 5,439

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 5,130

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 1,856

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences

Bone Metabolism and DiseasesOsteomyelitis and Bone Disorders Research

Cited by 1,636

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.

Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences

Bone Metabolism and DiseasesOsteomyelitis and Bone Disorders Research

Cited by 1,119

The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development.

Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell

Bone Metabolism and DiseasesEstrogen and related hormone effects

Cited by 756

197 POSTER Denosumab is a selective inhibitor of human receptor activator of NF-kB ligand that blocks osteoclast formation in vitro and in vivo

Elliott, R., Kostenuik, P., Chen, C., Kelley, M., Hawkins, N., Housman, J., McCabe, S., Mukku, V., Sullivan, J., & Dougall, W. (2006) · European Journal of Cancer Supplements

Head and Neck Cancer StudiesBone health and treatments

Cited by 14